Stockscreener 앱 받기
3.03
1.68%
0.05
시간 외 거래:
3.03
전일 마감가:
$2.98
열려 있는:
$3
하루 거래량:
403.92K
Relative Volume:
1.08
시가총액:
$236.72M
수익:
$351.37M
순이익/손실:
$-174.01M
주가수익비율:
-1.4638
EPS:
-2.07
순현금흐름:
$-126.94M
1주 성능:
-0.66%
1개월 성능:
-5.61%
6개월 성능:
+4.48%
1년 성능:
-10.88%
1일 변동 폭
$2.96
$3.06
1주일 범위
$2.925
$3.18
52주 변동 폭
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
명칭
Atea Pharmaceuticals Inc
전화
857-204-8109
주소
225 FRANKLIN STREET, BOSTON
AVIR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.03 | 232.82M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-10-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 개시 | Evercore ISI | Outperform |
| 2020-11-24 | 개시 | JP Morgan | Overweight |
| 2020-11-24 | 개시 | Morgan Stanley | Overweight |
| 2020-11-24 | 개시 | William Blair | Outperform |
모두보기
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
ReAlta Life Sciences (AVIR) appoints Dr. Howard Berman as Executive Chairman - Stock Titan
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharma (NASDAQ: AVIR) hosts Evercore fireside chat Dec. 3 at 10:00 a.m. ET - Stock Titan
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com
How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Live market analysis of Atea Pharmaceuticals Inc.CEO Change & AI Enhanced Market Trend Forecasts - newser.com
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism - MSN
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
What Makes HDFC Mutual fund a Strong Contender in YEAREarnings Call Summaries & Fast Growing Portfolio - earlytimes.in
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AVIR) 2025-11-14 - Seeking Alpha
Atea Pharmaceuticals Advances Antiviral Programs with New Data - TipRanks
Atea Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss By Investing.com - Investing.com Nigeria
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss - Investing.com
Atea Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report | AVIR SEC FilingForm 10-Q - Stock Titan
Atea Pharmaceuticals, Inc. (AVIR) Q3 FY2025 earnings call transcript - Yahoo Finance
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Atea Pharmaceuticals : Q3 Slides November 12 2025 FINAL - MarketScreener
[8-K] Atea Pharmaceuticals, Inc. Reports Material Event | AVIR SEC FilingForm 8-K - Stock Titan
Atea (Nasdaq: AVIR) says HCV Phase 3 on track; C-BEYOND topline results mid-2026 - Stock Titan
Atea Pharmaceuticals Inc (AVIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atea Pharmaceuticals Inc 주식 (AVIR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
0.53%
1.88%
자본화:
|
볼륨(24시간):